Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition

Drug-resistance is a major contributing factor for the poor prognosis in patients with pancreatic cancer. We have shown previously that the irreversible ErbB family blocker afatinib, is more effective than the reversible EGFR tyrosine kinase inhibitor erlotinib in inhibiting the growth of human panc...

Descripción completa

Detalles Bibliográficos
Autores principales: IOANNOU, NIKOLAOS, SEDDON, ALAN M., DALGLEISH, ANGUS, MACKINTOSH, DAVID, SOLCA, FLAVIO, MODJTAHEDI, HELMOUT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750538/
https://www.ncbi.nlm.nih.gov/pubmed/26781210
http://dx.doi.org/10.3892/ijo.2016.3320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750538/
https://www.ncbi.nlm.nih.gov/pubmed/26781210
http://dx.doi.org/10.3892/ijo.2016.3320

Ejemplares similares